Company intelligence / Profile preview

Degron Therapeutics

San Diego, California, United Statesprnewswire.com ↗

Ownership: Private
Development stage: Other

Overview

Lead program DEG6498 (HuR degrader) received FDA IND clearance in January 2025 to initiate clinical development in solid tumors. Phase 1/2 study enrollment expected to start in early 2025. WEE1 kinase degrader preclinical candidate expected to be selected in 1H 2025.

Therapeutic areas: OncologyRare DiseasesMetabolic DisordersImmunology
Modalities: Small molecule molecular glue degraders (MGDs)
Industry: Biotech

Drug pipeline

1 asset

DEG6498

Partnerships

Takeda Pharmaceutical Company Limited (multi-target collaboration announced May 2023, worth up to $1.2 billion)

Beyond the preview

Go deeper on Degron Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Degron Therapeutics.

Explore the full profile